Doxepin HCL Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2026 Edition
Doxepin HCL Price Trend, Index and Forecast
Track the latest insights on doxepin HCL price trend and forecast with detailed analysis of regional fluctuations and market dynamics across North America, Latin America, Central Europe, Western Europe, Eastern Europe, Middle East, North Africa, West Africa, Central and Southern Africa, Central Asia, Southeast Asia, South Asia, East Asia, and Oceania.
Doxepin HCL Prices Outlook Q2 2026
- USA: USD 198,318/MT
- China: USD 161,721/MT
- Germany: USD 193,209/MT
- Japan: USD 161,813/MT
- France: USD 202,497/MT
Doxepin HCL Price Chart
Get real-time access to monthly/quarterly/yearly prices Request Sample
During the second quarter of 2026, the doxepin HCL prices in the USA reached 198,318 USD/MT. Prices rose as high demand in the pharmaceutical industry and competitive manufacturing costs sustained buying interest. Doxepin HCL continued to hold a pivotal role in the treatment of psychiatric disorders, leading to steady consumption. Increasing production expenses due to raw material costs further contributed to the elevated price levels.
During the second quarter of 2026, the doxepin HCL prices in China reached 161,721 USD/MT. Prices climbed due to growing demand from the healthcare sector and rising production expenditures. Pharmaceutical manufacturers maintained a consistent procurement pattern for medications, aiding market activity. Adjustments in shipping lanes and port logistics occasionally posed challenges in cargo schedules and replacement provisions.
During the second quarter of 2026, the doxepin HCL prices in Germany reached 193,209 USD/MT in June. Prices showed an upward trend as constrained local supply and increased export queries stimulated the European market. Disruptions in supply chains and port traffic added complexity to material flow, raising concerns over replacement among healthcare sector buyers. Consistent demand, especially from mental health treatment products, was a significant driver.
During the second quarter of 2026, the doxepin HCL prices in Japan reached 161,813 USD/MT in June. Prices increased moderately with steady sourcing costs for imported materials and sustained demand for producing pharmaceutical compounds, influenced by stable consumption patterns. Regional logistics shifts and higher operational costs posed hurdles to timely supply, encouraging advance procurement planning.
During the second quarter of 2026, the doxepin HCL prices in France reached 202,497 USD/MT in June. Prices were augmented by heightened pharmaceutical production needs and sustained international demand. French producers were impacted by elevated logistics expenses, while domestic consumption for both local use and export maintained procurement pressure.
Doxepin HCL Prices Outlook Q4 2025
- USA: USD 182,636/MT
- China: USD 152,156/MT
- Germany: USD 183,758/MT
- Japan: USD 153,690/MT
- France: USD 187,382/MT
During the fourth quarter of 2025, the doxepin HCL prices in the USA reached 182,636 USD/MT in December. Prices edged higher as demand from pharmaceutical manufacturing and prescription drug formulation increased. Additionally, sustained production requirements from branded and generic drug manufacturers supported procurement activity. Moreover, sourcing behavior reflected the need to secure consistent volumes aligned with regulated manufacturing schedules and compliance-driven inventory planning.
During the fourth quarter of 2025, the doxepin HCL prices in China reached 152,156 USD/MT in December. Prices edged lower as demand from export-oriented pharmaceutical intermediates and API manufacturing softened. Furthermore, adequate availability across domestic producers reduced buying pressure. In addition, procurement volumes were adjusted to align with cautious inventory management and moderated downstream production activity.
During the fourth quarter of 2025, the doxepin HCL prices in Germany reached 183,758 USD/MT in December. Prices advanced as consumption from pharmaceutical formulation and specialty drug manufacturing strengthened. Additionally, stringent quality and regulatory requirements encouraged consistent procurement. Moreover, sourcing strategies emphasized supply reliability and alignment with planned production runs across regulated pharmaceutical facilities.
During the fourth quarter of 2025, the doxepin HCL prices in Japan reached 153,690 USD/MT in December. Prices trended downward as demand from pharmaceutical manufacturing and hospital supply chains moderated. Furthermore, sufficient domestic and import availability eased sourcing pressure. In addition, procurement behavior reflected inventory optimization and alignment with near-term prescription demand visibility.
During the fourth quarter of 2025, the doxepin HCL prices in France reached 187,382 USD/MT in December. Prices rose supported by steady demand from pharmaceutical formulation, clinical supply requirements, and regulated drug manufacturing. Moreover, compliance-driven sourcing and quality assurance needs sustained procurement activity. Additionally, purchasing decisions emphasized inventory coverage and coordination with validated production schedules.
Doxepin HCL Prices Outlook Q3 2025
- USA: USD 176,460/MT
- China: USD 157,024/MT
- Germany: USD 179,101/MT
- Japan: USD 158,935/MT
- France: USD 182,456/MT
During the third quarter of 2025, the doxepin HCL prices in the USA reached 176,460 USD/MT in September. Prices rose as pharmaceutical hubs expanded procurement and feedstock availability steadied. Inland transport congestion caused minor delays, and contract manufacturers increased scheduled offtake, encouraging more orderly sourcing.
During the third quarter of 2025, the doxepin HCL prices in China reached 157,024 USD/MT in September. The upward movement followed tighter production planning at API facilities and firm export interest. Port-handling delays affected outbound flow, while downstream formulators aligned purchases with consistent output requirements.
During the third quarter of 2025, the doxepin HCL prices in Germany reached 179,101 USD/MT in September. Prices increased as local healthcare manufacturing strengthened and import-driven facilities saw staggered shipment timings. Slight tightening in specialty input access encouraged more deliberate procurement among larger formulators.
During the third quarter of 2025, the doxepin HCL prices in Japan reached 158,935 USD/MT in September. Prices strengthened as formulation plants elevated restocking and exchange-rate-sensitive import costs shaped ordering. Port-side berth variability influenced unloading times, prompting more careful coordination of incoming shipments.
During the third quarter of 2025, the doxepin HCL prices in France reached 182,456 USD/MT in September. The upward movement reflected stable medicine output and localized tightness across distributor networks. Buyers diversified supply sources and adjusted scheduling to secure material amid shifting channel availability.
Doxepin HCL Prices Outlook Q2 2025
- USA: USD 172,814/MT
- China: USD 154,096/MT
- Germany: USD 175,572/MT
- Japan: USD 157,533/MT
- France: USD 180,453/MT
During the second quarter of 2025, the doxepin HCL prices in the USA reached 172,814 USD/MT in June. Contracting routines guided purchasing volumes, while production variability affected inflows to distributors. Logistics inconsistencies required schedule adjustments, shaping a steady, efficiency-focused procurement environment.
During the second quarter of 2025, the doxepin HCL prices in China reached 154,096 USD/MT in June. API facilities adjusted operations, influencing availability for domestic and export markets. Freight timing volatility at major ports shaped buyer planning, while downstream formulators balanced inventories with revised production schedules.
During the second quarter of 2025, the doxepin HCL prices in Germany reached 175,572 USD/MT in June. Consistent healthcare demand supported transactional activity, and formulators recalibrated procurement to align with processing needs. Varied import lead times encouraged more careful inventory management across facilities.
During the second quarter of 2025, the doxepin HCL prices in Japan reached 157,533 USD/MT in June. Downstream manufacturers adjusted production cycles and managed uneven shipment flow. Currency-linked considerations influenced import planning, contributing to measured purchasing behavior.
During the second quarter of 2025, the doxepin HCL prices in France reached 180,453 USD/MT in June. Distributor-level availability fluctuated, prompting formulators to align orders with evolving supply access. These adjustments supported stable procurement in line with domestic pharmaceutical needs.
Regional Coverage
The report provides a detailed analysis of the market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast, and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of FOB and CIF prices, as well as the key factors influencing doxepin HCL prices.
Europe Doxepin HCL Price Trend
Q2 2026:
The doxepin HCL price index in Europe moved upward as local availability remained limited and export demand picked up. Some suppliers faced tighter inventories, which reduced the amount of material available for prompt delivery and encouraged buyers to secure stocks earlier. Port congestion and occasional transport delays also affected shipment schedules, adding pressure to delivered costs and making replacement purchases more expensive. Feedstock price movements continued to influence manufacturing costs, keeping producer margins under pressure even as some input costs became more stable toward the end of the quarter. Demand from pharmaceutical manufacturers remained steady, supported by continued requirements for psychiatric medicines and related formulations.
Q4 2025:
As per the doxepin HCL price index, prices across Europe strengthened, supported by sustained demand from regulated pharmaceutical manufacturing, specialty drug formulation, and hospital supply chains. Additionally, strict regulatory oversight, batch traceability requirements, and pharmacopoeia compliance shaped sourcing behavior across the region. Moreover, procurement strategies prioritized supply reliability, validated supplier relationships, and alignment with approved production schedules, while inventory planning focused on ensuring uninterrupted availability for prescription drug manufacturing rather than engaging in opportunistic spot buying.
Q3 2025:
Prices increased as procurement strengthened across major formulation hubs and select intermediates showed tighter availability. Rail and road transit variability in central and northern Europe encouraged manufacturers to maintain broader inventory buffers and diversify inbound routes. Pharmaceutical producers leaned on more stable import corridors as freight scheduling grew less predictable, especially for controlled-substance APIs. Consistent offtake from mental-health medicine lines supported firmer sentiment, shaping disciplined sourcing across the region.
Q2 2025:
Market activity was shaped by steady demand from regulated pharmaceutical manufacturers and intermittent variability in imported API access. Formulators adjusted procurement schedules to cope with uneven raw-material flows at major continental entry points, and distributors adapted warehousing practices to smooth intake volumes. Regulatory compliance and quality-assurance checks continued to guide sourcing choices, encouraging structured acquisition routines aligned with production planning.
This analysis can be extended to include detailed doxepin HCL price information for a comprehensive list of countries.
| Region | Countries Covered |
|---|---|
| Europe | Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal, and Greece, among other European countries. |
North America Doxepin HCL Price Trend
Q2 2026:
The doxepin HCL price index in North America rose significantly as immediate supply remained tight and demand from pharmaceutical manufacturers stayed firm. Limited spot availability made it harder for buyers to source material quickly, particularly when regular shipments were delayed or inventories were already committed. Export orders also absorbed part of the available regional supply, leaving less flexibility for domestic spot purchases. Higher raw material, freight, warehousing, and other logistics expenses added further pressure to replacement costs. Pharmaceutical companies responded by placing orders earlier and maintaining more secure inventory levels to avoid supply interruptions.
Q4 2025:
As per the doxepin HCL price index, prices in North America increased, driven by continued consumption from prescription drug manufacturing, branded formulations, and generic pharmaceutical production. Furthermore, steady demand from healthcare systems and pharmacy distribution channels supported consistent procurement activity. In addition, sourcing strategies emphasized contract-based supply, regulatory compliance, and inventory planning aligned with prescription volumes and downstream production visibility, ensuring continuity across tightly regulated pharmaceutical supply chains.
Q3 2025:
Prices moved higher as formulation units increased orders and distribution channels encountered selective constraints. Freight congestion along key west-to-central corridors created delays in material repositioning, prompting buyers to extend planning horizons. API plants adjusted production around evolving contract loads, maintaining controlled output to suit consistent downstream requirements. These logistics and manufacturing dynamics encouraged risk-aware procurement strategies across the region.
Q2 2025:
In North America, operational stability at leading API producers underpinned consistent allocation planning for doxepin HCL across hospital and contract-manufacturing channels. Buyers emphasized continuity of supply, aligning orders with predictable manufacturing cycles and controlled output from domestic facilities. Logistics providers maintained focus on reliability, coordinating inland freight and port operations to support steady material distribution.
Specific doxepin HCL historical data within the United States and Canada can also be provided.
| Region | Countries Covered |
|---|---|
| North America | United States and Canada |
Middle East and Africa Doxepin HCL Price Trend
Q2 2026:
The study includes doxepin HCL price trends across the Middle East and Africa, considering factors such as industrial growth, local resource management, and international trade policies impacting market prices.
Q4 2025:
As per doxepin HCL price chart, the prices in the Middle East and Africa fluctuated due to a complex interplay of factors, primarily driven by supply chain disruptions, seasonal demand shifts, and geopolitical influences.
Q3 2025:
The report explores the doxepin HCL pricing trends and doxepin HCL price chart in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices.
In addition to region-wise data, information on doxepin HCL prices for countries can also be provided.
| Region | Countries Covered |
|---|---|
| Middle East & Africa | Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco, among other Middle Eastern and African countries. |
Asia Pacific Doxepin HCL Price Trend
Q2 2026:
Doxepin HCL prices in Asia Pacific showed an upward trend as increased production costs and robust demand in the pharmaceutical sector bolstered the market. China faced limited immediate availability and stronger production economics throughout much of the quarter, while shipping constraints and port congestion occasionally limited cargo movement. Japan encountered higher import replacement costs and unpredictable freight conditions, prompting buyers to maintain planned procurement schedules. Demand from the pharmaceutical industry, specifically for the treatment of anxiety and depression, provided a stable consumption base across the region. Providers upheld disciplined offers as input costs stayed elevated.
Q4 2025:
Across Asia Pacific, doxepin HCL prices moved lower as demand from pharmaceutical manufacturing, export-oriented API production, and domestic drug formulation softened. Furthermore, moderated procurement activity reflected cautious inventory management amid sufficient regional availability. In addition, sourcing strategies emphasized cost control, inventory visibility, and alignment with reduced downstream production schedules, particularly within markets focused on export APIs and hospital-grade pharmaceutical supply.
Q3 2025:
Prices strengthened as major API production hubs in East and South Asia adjusted operations amid evolving feedstock and processing conditions. Import-dependent economies across Southeast Asia faced inconsistent landed costs and irregular cargo arrival patterns, prompting phased and closely timed procurement cycles. Large-scale formulation clusters in India, China, and Japan sustained high offtake, reinforcing regional demand. These factors encouraged buyers to adopt more strategic sourcing approaches across multiple supply origins.
Q2 2025:
Across Asia Pacific, sourcing behavior reflected a mix of robust offtake in large formulation centers and uneven inventory positions at smaller manufacturing hubs. Procurement timing was coordinated to match plant-level operational rhythms, and import-dependent markets factored freight cost variability into sourcing decisions. The combined influence of local production dynamics and cross-border logistics encouraged a layered approach to supply assurance.
This doxepin HCL price analysis can be expanded to include a comprehensive list of countries within the region.
| Region | Countries Covered |
|---|---|
| Asia Pacific | China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand, among other Asian countries. |
Latin America Doxepin HCL Price Trend
Q2 2026:
The doxepin HCL market in Latin America is primarily driven by the region's growing healthcare infrastructure, especially in Brazil. However, due to economic challenges and political uncertainties, Doxepin HCL prices might experience considerable fluctuations.
Q4 2025:
Latin America's doxepin HCL market is predominantly influenced by its rich natural reserves, particularly in countries like Chile and Brazil. However, political instability and inconsistent regulatory frameworks can lead to significant volatility in doxepin HCL prices.
Q3 2025:
Infrastructure challenges and logistical inefficiencies often impact the supply chain, affecting Latin America’s ability to meet international demand consistently. Moreover, the doxepin HCL price index, economic fluctuations, and currency devaluation are critical factors that need to be considered when analyzing doxepin HCL pricing trends in this region.
This comprehensive review can be extended to include specific countries within the region.
| Region | Countries Covered |
|---|---|
| Latin America | Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru, among other Latin American countries. |
Doxepin HCL Pricing Report, Market Analysis, and News
IMARC's latest publication, “Doxepin HCL Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2026 Edition,” offers a detailed exploration of the doxepin HCL market, providing insights into both global and regional trends that are influencing prices. This report examines the spot price of doxepin HCL at major markets and provides in-depth price composition analysis, including FOB and CIF terms. It also presents a detailed doxepin HCL price trend analysis by region, covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The factors impacting doxepin HCL pricing, including supply and demand dynamics, geopolitical influences, and industry-specific developments, are thoroughly examined. This comprehensive report aids stakeholders in staying informed with the latest market news, regulatory updates, and technological advancements, facilitating informed strategic decision-making and forecasting.
Doxepin HCL Industry Analysis
The global doxepin HCL market size reached USD 507.22 Million in 2025. By 2034, IMARC Group expects the market to reach USD 671.05 Million, at a projected CAGR of 3.16% during 2026-2034. The market is primarily driven by the rising demand for effective treatments for psychiatric disorders, increased focus on mental health awareness, and the expanding application of pharmaceuticals incorporating doxepin HCL.
Latest News and Developments:
- November 2025: Researchers at Shenzhen Technology reported that doxepin demonstrated antiviral potential by targeting host AXL kinase to disrupt coxsackievirus B infection. The study showed that doxepin reduced viral entry and replication in preclinical models. This finding suggested a promising R&D direction for expanding the therapeutic applications of the drug beyond its traditional psychiatric and insomnia uses.
Product Description
Doxepin HCL is a tricyclic antidepressant mainly used to treat major depressive disorder and certain anxiety related conditions. It works by reducing the reuptake of norepinephrine and serotonin in the brain, which helps increase their availability between nerve cells. At lower doses, doxepin is also prescribed for insomnia, particularly in patients who have difficulty staying asleep. The compound also has strong antihistamine properties and is used in topical formulations to relieve itching linked to certain skin disorders. Doxepin HCL is available in oral and topical forms, with applications across psychiatric and dermatological treatments. Its established clinical use supports steady demand from pharmaceutical manufacturers.
Report Coverage
| Key Attributes | Details |
|---|---|
| Product Name | Doxepin HCL |
| Report Features | Exploration of Historical Trends and Market Outlook, Industry Demand, Industry Supply, Gap Analysis, Challenges, Doxepin HCL Price Analysis, and Segment-Wise Assessment. |
| Currency/Units | US$ (Data can also be provided in local currency) or Metric Tons |
| Region/Countries Covered | The current coverage includes analysis at the global and regional levels only. Based on your requirements, we can also customize the report and provide specific information for the following countries: Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece North America: United States and Canada Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco The list of countries presented is not exhaustive. Information on additional countries can be provided if required by the client. |
| Information Covered for Key Suppliers |
|
| Customization Scope | The report can be customized as per the requirements of the customer |
| Report Price and Purchase Option |
Plan A: Monthly Updates - Annual Subscription
Plan B: Quarterly Updates - Annual Subscription
Plan C: Biannually Updates - Annual Subscription
|
| Post-Sale Analyst Support | 360-degree analyst support after report delivery |
| Delivery Format | PDF and Excel through email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Benefits for Stakeholders:
- IMARC’s report presents a detailed analysis of doxepin HCL pricing, covering global and regional trends, spot prices at key ports, and a breakdown of Ex Works, FOB, and CIF prices.
- The study examines factors affecting doxepin HCL price trend, including raw material costs, supply-demand shifts, geopolitical impacts, and industry developments, offering insights for informed decision-making.
- The competitive landscape review equips stakeholders with crucial insights into the latest market news, regulatory changes, and technological advancements, ensuring a well-rounded, strategic overview for forecasting and planning.
- IMARC offers various subscription options, including monthly, quarterly, and biannual updates, allowing clients to stay informed with the latest market trends, ongoing developments, and comprehensive market insights. The doxepin HCL price charts ensure our clients remain at the forefront of the industry.
Need more help?
- Speak to our experienced analysts for insights on the current market scenarios.
- Include additional segments and countries to customize the report as per your requirement.
- Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
- For further assistance, please connect with our analysts.
Request Customization
Inquire Before Buying
Speak to an Analyst
Request Brochure
Benefits of Customization
- Personalize this research
- Triangulate with your data
- Get data as per your format and definition
- Gain a deeper dive into a specific application, geography, customer, or competitor
- Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-201-971-6302
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-714-6104
Email: [email protected]
Client Testimonials
.webp)
.webp){kind=logo}
Related Reports
Why Choose Us
IMARC offers trustworthy, data-centric insights into commodity pricing and evolving market trends, enabling businesses to make well-informed decisions in areas such as procurement, strategic planning, and investments. With in-depth knowledge spanning more than 1000 commodities and a vast global presence in over 150 countries, we provide tailored, actionable intelligence designed to meet the specific needs of diverse industries and markets.
1000
+Commodities
150
+Countries Covered
3000
+Clients
20
+Industry
Robust Methodologies & Extensive Resources
IMARC delivers precise commodity pricing insights using proven methodologies and a wealth of data to support strategic decision-making.
Subscription-Based Databases
Our extensive databases provide detailed commodity pricing, import-export trade statistics, and shipment-level tracking for comprehensive market analysis.
Primary Research-Driven Insights
Through direct supplier surveys and expert interviews, we gather real-time market data to enhance pricing accuracy and trend forecasting.
Extensive Secondary Research
We analyze industry reports, trade publications, and market studies to offer tailored intelligence and actionable commodity market insights.
Trusted by 3000+ industry leaders worldwide to drive data-backed decisions. From global manufacturers to government agencies, our clients rely on us for accurate pricing, deep market intelligence, and forward-looking insights.